Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Siegel, Georg ^a   Kluba, Torsten ^a   Hermanutz Klein, Ursula ^a   Bieback, Karen ^b   Northoff, Hinnak ^a   Schäfer, Richard ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Differentiation; Gender; Immunomodulation; Mesenchymal stromal stem cells; Phenotype

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA INTEGRIN; CD146 ANTIGEN; CD71 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON RECEPTOR 1; HLA ANTIGEN; INTERLEUKIN 6; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TELOMERASE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL POPULATION; CELL SIZE; COCULTURE; COLONY FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DONOR; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENDER; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STROMA CELL; MESODERM; PHENOTYPE; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SEX DIFFERENCE; T CELL DEPLETION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOPHENOTYPING; LIVING DONORS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; SEX FACTORS; YOUNG ADULT;

EID: 84878687011     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-146     Document Type: Article

References (77)

1. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247. 10.1097/00007890-196803000-00009, 5654088.
2. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17:331-340. 10.1097/00007890-197404000-00001, 4150881.
3. Muguruma Y, Yahata T, Miyatake H, Sato T, Uno T, Itoh J, Kato S, Ito M, Hotta T, Ando K. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood 2006, 107:1878-1887. 10.1182/blood-2005-06-2211, 16282345.
4. Miura Y, Miura M, Gronthos S, Allen MR, Cao C, Uveges TE, Bi Y, Ehirchiou D, Kortesidis A, Shi S, Zhang L. Defective osteogenesis of the stromal stem cells predisposes CD18-null mice to osteoporosis. Proc Natl Acad Sci U S A 2005, 102:14022-14027. 10.1073/pnas.0409397102, 1236524, 16172402.
5. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937. 10.1073/pnas.132252399, 124401, 12084934.
6. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O, Developmental Committee of the European Group for Blood and Marrow Transplantation Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586. 10.1016/S0140-6736(08)60690-X, 18468541, Developmental Committee of the European Group for Blood and Marrow Transplantation.
7. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011, 109:923-940. 10.1161/CIRCRESAHA.111.243147, 3604746, 21960725.
8. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669. 10.1136/gut.2010.215152, 20921206.
9. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the international MSCT study group. Mult Scler 2010, 16:503-510. 10.1177/1352458509359727, 20086020.
10. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007, 25:2896-2902. 10.1634/stemcells.2007-0637, 17901396.
11. Phinney DG, Kopen G, Righter W, Webster S, Tremain N, Prockop DJ. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem 1999, 75:424-436. 10.1002/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.0.CO;2-8, 10536366.
12. Russell KC, Phinney DG, Lacey MR, Barrilleaux BL, Meyertholen KE, O'Connor KC. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010, 28:788-798. 10.1002/stem.312, 20127798.
13. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002, 30:783-791. 10.1016/S0301-472X(02)00812-3, 12135677.
14. Schäfer R, Schnaidt M, Klaffschenkel RA, Siegel G, Schüle M, Rädlein MA, Hermanutz-Klein U, Ayturan M, Buadze M, Gassner C, Danielyan L, Kluba T, Northoff H, Flegel WA. Expression of blood group genes by mesenchymal stem cells. Br J Haematol 2011, 153:520-528. 10.1111/j.1365-2141.2011.08652.x, 3080447, 21418181.
15. Schäfer R, Dominici M, Müller I, Horwitz E, Asahara T, Bulte JW, Bieback K, Le Blanc K, Bühring HJ, Capogrossi MC, Dazzi F, Gorodetsky R, Henschler R, Handgretinger R, Kajstura J, Kluger PJ, Lange C, Luettichau I, Mertsching H, Schrezenmeier H, Sievert KD, Strunk D, Verfaillie C, Northoff H. Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany. Cytotherapy 2009, 11:245-255. 10.1080/14653240802582117, 19152153.
16. Bianco P, Barker R, Brustle O, Cattaneo E, Clevers H, Daley GQ, De Luca M, Goldstein L, Lindvall O, Mummery C, Robey PG, Sattler de Sousa E Brito C, Smith A. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J 2013, Epub ahead of print.
17. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317. 10.1080/14653240600855905, 16923606.
18. Siegel G, Schäfer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 2009, 87(9 Suppl):S45-S49.
19. Siegel G, Krause P, Wohrle S, Nowak P, Ayturan M, Kluba T, Brehm BR, Neumeister B, Kohler D, Rosenberger P, Just L, Northoff H, Schäfer R. Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev 2012, 21:2457-2470. 10.1089/scd.2011.0626, 22309203.
20. Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J 2004, 18:980-982.
21. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98:1076-1084. 10.1002/jcb.20886, 16619257.
22. Doorn J, Moll G, Le Blanc K, van Blitterswijk C, de Boer J. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev 2012, 18:101-115. 10.1089/ten.teb.2011.0488, 21995703.
23. Cox G, Boxall SA, Giannoudis PV, Buckley CT, Roshdy T, Churchman SM, McGonagle D, Jones E. High abundance of CD271(+) multipotential stromal cells (MSCs) in intramedullary cavities of long bones. Bone 2012, 50:510-517. 10.1016/j.bone.2011.07.016, 3268250, 21807134.
24. Churchman SM, Ponchel F, Boxall SA, Cuthbert R, Kouroupis D, Roshdy T, Giannoudis PV, Emery P, McGonagle D, Jones EA. Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. Arthritis Rheum 2012, 64:2632-2643. 10.1002/art.34434, 22378497.
25. Dominici M, Paolucci P, Conte P, Horwitz EM. Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. Transplantation 2009, 87(9 Suppl):S36-S42.
26. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000, 113:1161-1166.
27. Russell KC, Lacey MR, Gilliam JK, Tucker HA, Phinney DG, O'Connor KC. Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency. Biotechnol Bioeng 2011, 108:2716-2726. 10.1002/bit.23193, 3178709, 21538337.
28. da Silva ML, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299. 10.1634/stemcells.2007-1122, 18566331.
29. Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford) 2008, 47:126-131.
30. Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Muller I, Schewe B, Skutella T, Fibbe WE, Kanz L, Bühring HJ. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 2009, 94:173-184. 10.3324/haematol.13740, 2635396, 19066333.
31. Bühring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007, 1106:262-271. 10.1196/annals.1392.000, 17395729.
32. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007, 109:4245-4248. 10.1182/blood-2006-08-039347, 1885494, 17264296.
33. Schäfer R. Does the adult stroma contain stem cells?. Adv Biochem Eng Biotechnol 2013, 129:177-189.
34. Phinney DG. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 2012, 113:2806-2812. 10.1002/jcb.24166, 22511358.
35. Buick RN, MacKillop WJ. Measurement of self-renewal in culture of clonogenic cells from human ovarian carcinoma. Br J Cancer 1981, 44:349-355. 10.1038/bjc.1981.191, 2010772, 7284232.
36. Thomson SP, Meyskens FL. Method for measurement of self-renewal capacity of clonogenic cells from biopsies of metastatic human malignant melanoma. Cancer Res 1982, 42:4606-4613.
37. Rose RA, Jiang H, Wang X, Helke S, Tsoporis JN, Gong N, Keating SC, Parker TG, Backx PH, Keating A. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 2008, 26:2884-2892. 10.1634/stemcells.2008-0329, 18687994.
38. Henderson JK, Draper JS, Baillie HS, Fishel S, Thomson JA, Moore H, Andrews PW. Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Stem Cells 2002, 20:329-337. 10.1634/stemcells.20-4-329, 12110702.
39. Tsuneyoshi N, Sumi T, Onda H, Nojima H, Nakatsuji N, Suemori H. PRDM14 suppresses expression of differentiation marker genes in human embryonic stem cells. Biochem Biophys Res Commun 2008, 367:899-905. 10.1016/j.bbrc.2007.12.189, 18194669.
40. Battula VL, Bareiss PM, Treml S, Conrad S, Albert I, Hojak S, Abele H, Schewe B, Just L, Skutella T, Bühring HJ. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation 2007, 75:279-291. 10.1111/j.1432-0436.2006.00139.x, 17288545.
41. Fazzi R, Pacini S, Carnicelli V, Trombi L, Montali M, Lazzarini E, Petrini M. Mesodermal progenitor cells (MPCs) differentiate into mesenchymal stromal cells (MSCs) by activation of Wnt5/calmodulin signalling pathway. PLoS One 2011, 6:e25600. 10.1371/journal.pone.0025600, 3183072, 21980498.
42. Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, Roberts SJ, Luyten FP, Van Gool SW, Sampaolesi M, Delforge M, Luttun A, Verfaillie CM. Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 2011, 29:871-882. 10.1002/stem.633, 21433224.
43. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49. Erratum in: Nature 2007, 447:879-880, 10.1038/nature00870, 12077603.
44. Serafini M, Dylla SJ, Oki M, Heremans Y, Tolar J, Jiang Y, Buckley SM, Pelacho B, Burns TC, Frommer S, Rossi DJ, Bryder D, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Nelson-Holte M, Fine GC, Weissman IL, Blazar BR, Verfaillie CM. Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. J Exp Med 2007, 204:129-139. 10.1084/jem.20061115, 2118428, 17227908.
45. D'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004, 117:2971-2981. 10.1242/jcs.01103, 15173316.
46. Kucia M, Halasa M, Wysoczynski M, Baskiewicz-Masiuk M, Moldenhawer S, Zuba-Surma E, Czajka R, Wojakowski W, Machalinski B, Ratajczak MZ. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia 2007, 21:297-303. 10.1038/sj.leu.2404470, 17136117.
47. Kucia M, Reca R, Campbell FR, Zuba-Surma E, Majka M, Ratajczak J, Ratajczak MZ. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006, 20:857-869. 10.1038/sj.leu.2404171, 16498386.
48. Rasini V, Dominici M, Kluba T, Siegel G, Lusenti G, Northoff H, Horwitz EM, Schäfer R. Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy 2013, 15:292-306. 10.1016/j.jcyt.2012.11.009, 23312449.
49. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150. 10.1016/j.stem.2007.11.014, 18371435.
50. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441. 10.1016/S0140-6736(04)16104-7, 15121408.
51. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11:150-156. 10.1016/S1474-4422(11)70305-2, 3279697, 22236384.
52. Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 2011, 12:62. 10.1186/1745-6215-12-62, 3059276, 21366911.
53. Löb S, Konigsrainer A, Schäfer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008, 111:2152-2154. 10.1182/blood-2007-10-116111, 18045970.
54. Francois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012, 20:187-195. 10.1038/mt.2011.189, 21934657.
55. Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116:3770-3779. 10.1182/blood-2010-02-270777, 20644118.
56. Mourcin F, Breton C, Tellier J, Narang P, Chasson L, Jorquera A, Coles M, Schiff C, Mancini SJ. Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. Blood 2011, 117:6552-6561. 10.1182/blood-2010-12-323113, 21511956.
57. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 2011, 1217:45-59. 10.1111/j.1749-6632.2010.05919.x, 21276005.
58. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005, 35:1482-1490. 10.1002/eji.200425405, 15827960.
59. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009, 183:993-1004. 10.4049/jimmunol.0900803, 19561093.
60. Choumerianou DM, Martimianaki G, Stiakaki E, Kalmanti L, Kalmanti M, Dimitriou H. Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults. Cytotherapy 2010, 12:881-887. 10.3109/14653249.2010.501790, 20662612.
61. Alves H, van Ginkel J, Groen N, Hulsman M, Mentink A, Reinders M, van Blitterswijk C, de Boer J. A mesenchymal stromal cell gene signature for donor age. PLoS One 2012, 7:e42908. 10.1371/journal.pone.0042908, 3426516, 22927939.
62. Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Ishii K, Kobune M, Hirai S, Uchida H, Sasaki K, Ito Y, Kato K, Honmou O, Houkin K, Date I, Hamada H. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 2005, 11:96-104.
63. Nomura T, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience 2005, 136:161-169. 10.1016/j.neuroscience.2005.06.062, 2605391, 16229956.
64. Nguyen BK, Maltais S, Perrault LP, Tanguay JF, Tardif JC, Stevens LM, Borie M, Harel F, Mansour S, Noiseux N. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res 2010, 3:547-558. 10.1007/s12265-010-9171-0, 20559784.
65. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008, 47:1634-1643. 10.1002/hep.22236, 18395843.
66. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011, 29:913-919. 10.1002/stem.643, 3293251, 21506195.
67. Crisostomo PR, Wang M, Herring CM, Morrell ED, Seshadri P, Meldrum KK, Meldrum DR. Sex dimorphisms in activated mesenchymal stem cell function. Shock 2006, 26:571-574. 10.1097/01.shk.0000233195.63859.ef, 17117131.
68. Crisostomo PR, Wang M, Herring CM, Markel TA, Meldrum KK, Lillemoe KD, Meldrum DR. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). J Mol Cell Cardiol 2007, 42:142-149. 10.1016/j.yjmcc.2006.09.016, 1779905, 17070836.
69. Chen DF, Du SH, Zhang HL, Li H, Zhou JH, Li YW, Yi XH, Hou QK, Wu J, Zeng HP, Hua ZC. Autocrine BMP4 signaling involves effect of cholesterol myristate on proliferation of mesenchymal stem cells. Steroids 2009, 74:1066-1072. 10.1016/j.steroids.2009.08.008, 19723531.
70. Wislet-Gendebien S, Bruyere F, Hans G, Leprince P, Moonen G, Rogister B. Nestin-positive mesenchymal stem cells favour the astroglial lineage in neural progenitors and stem cells by releasing active BMP4. BMC Neurosci 2004, 5:33. 10.1186/1471-2202-5-33, 520747, 15369599.
71. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008, 112:295-307. 10.1182/blood-2007-07-103697, 18332228.
72. Fekete N, Gadelorge M, Fürst D, Maurer C, Dausend J, Fleury-Cappellesso S, Mailänder V, Lotfi R, Ignatius A, Sensebé L, Bourin P, Schrezenmeier H, Rojewski MT. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554. 10.3109/14653249.2012.655420, 3400099, 22296115.
73. Kim JH, Lee MC, Seong SC, Park KH, Lee S. Enhanced proliferation and chondrogenic differentiation of human synovium-derived stem cells expanded with basic fibroblast growth factor. Tissue Eng Part A 2011, 17:991-1002. 10.1089/ten.tea.2010.0277, 21091327.
74. Lai WT, Krishnappa V, Phinney DG. Fibroblast growth factor 2 (Fgf2) inhibits differentiation of mesenchymal stem cells by inducing Twist2 and Spry4, blocking extracellular regulated kinase activation, and altering Fgf receptor expression levels. Stem Cells 2011, 29:1102-1111. 10.1002/stem.661, 3410557, 21608080.
75. Coutu DL, Francois M, Galipeau J. Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood 2011, 117:6801-6812. 10.1182/blood-2010-12-321539, 21527526.
76. Gupta V, Bhasin S, Guo W, Singh R, Miki R, Chauhan P, Choong K, Tchkonia T, Lebrasseur NK, Flanagan JN, Hamilton JA, Viereck JC, Narula NS, Kirkland JL, Jasuja R. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 2008, 296:32-40. 10.1016/j.mce.2008.08.019, 2873614, 18801408.
77. Breu A, Sprinzing B, Merkl K, Bechmann V, Kujat R, Jenei-Lanzl Z, Prantl L, Angele P. Estrogen reduces cellular aging in human mesenchymal stem cells and chondrocytes. J Orthop Res 2011, 29:1563-1571. 10.1002/jor.21424, 21469181.